À titre de membre permanent, vous pourrez accéder au contenu éditorial et de formation continue, utiliser le moteur de recherche, recevoir nos newsletters, participer aux discussions, télécharger des diapositives et plus encore.
A new analysis of the EXPRESS study confirms that early aggressive treatment of patients with transient ischemic attacks or minor stroke can cut recurrent stroke risk at 90 days by about 80%, but by four years, the risk returns to quite high levels.
A study suggests that transcranial Doppler helps target patients with asymptomatic carotid stenosis at higher risk for events who might benefit from intervention and identifies those at low risk for stroke.
A new analysis of SITS registry data since release of studies showing benefit from thrombolysis out to 4.5 hours finds increased use of tPA in all time frames, with no indication that doctors are taking additional time deciding whether to treat.
One of the largest stroke trials to date not funded by industry shows once again no significant benefit of supplementation with B vitamins in patients with recent stroke or TIA.
Patients with atrial fibrillation enrolled in the ROCKET-AF trial—looking at whether the novel anticoagulant rivaroxaban is better than warfarin for preventing stroke—are at higher risk of stroke than those who have participated in other recent trials of novel agents for this indication.
The CREST trial, first reported in February, showed similar net outcomes for carotid stenting vs endarterectomy, but editorialists say they are sticking with surgery for symptomatic disease.
